🇺🇸 PA32540 in United States

FDA authorised PA32540 on 14 September 2016

Marketing authorisation

FDA — authorised 14 September 2016

  • Application: NDA205103
  • Marketing authorisation holder: GENUS LIFESCIENCES
  • Local brand name: YOSPRALA
  • Indication: TABLET, DELAYED RELEASE — ORAL
  • Status: approved

Read official source →

Other Pain Management approved in United States

Frequently asked questions

Is PA32540 approved in United States?

Yes. FDA authorised it on 14 September 2016.

Who is the marketing authorisation holder for PA32540 in United States?

GENUS LIFESCIENCES holds the US marketing authorisation.